Presented by
William Hollifield, MD
Assistant Professor
Department of Psychiatry
University of Florida
Target Audience
Primary Care Physicians
Price
$0 for UF Participants
$35.00 non-UF Participants
Program Description
This CME activity consists of an educational component (slides, audio lecture) in an electronic format, followed by an online post-test. Estimated time to complete this activity, including review of materials, is one hour.
Requirements for Successful Completion
- This CME activity consists of an educational component (audio lecture in an electronic format, which is followed by an online post-test).
- Certificates are awarded upon successful completion (80% proficiency) of the post-test.
- In order to receive credit, participants must view the presentation in its entirety.
- The University of Florida College of Medicine will report CME credit to CE Broker when applicable.
Learning Objectives
As a result of participation in this activity, participants should be able to:
Define the pharmacological properties and the physiological effects of buprenorphine.
2.Describe the potential benefits and risks of buprenorphine.
.Review the use of buprenorphine in managing opiate use disorder.
4.Assess the use of buprenorphine in both hospital and outpatient settings.
Faculty Disclosure
Dr. Hollifield has disclosed that he has no relevant financial relationships. Dr. Bussing has disclosed that she has received research support from Pfizer. No one else in a position to control the content of this activity has any financial relationships to disclose.
Continuing Medical Education Credit
Accreditation: The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit: The University of Florida College of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Release Date: February 5, 2018
Expiration Date: February 4, 2020